Lilly, Alkermes end partnership on inhaled insulin

Eli Lilly and Co. says it is ending its partnership with biotech firm Alkermes to develop AIR Insulin, an inhaled insulin product. Two other companies, Pfizer and Novo Nordisk A/S, have also said they would discontinue trials of similar drug candidates. Alkermes said that the withdrawal was not due to safety or efficacy concerns, while a Lilly spokesman cited "new uncertainties in the regulatory environment" as a factor in its decision.

View Full Article in:

Wall Street Journal (free content), The · Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Operating Officer
Health Plan of San Joaquin
French Camp , CA
Actuary
NTA Life
Addison, TX
Chief Information Officer
Meridian Health Plan
Detroit, MI
Vice President - Government Products
Health Alliance Plan
Detroit, MI
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA